CSI Market
Sign In | Register

Cidara Therapeutics Inc (CDTX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CDTX Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Cidara Therapeutics Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2025)
9 Months 		(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Operating Activities
Income-132.43
Depreciation & amortization0.09
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.05
Share-based Compensation7.87
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.01
Noncash Derivative Issuance Cost-
Increase Decrease In Accounts Receivable Prepaid Expenses Other Current Assets And Other Assets-
Operating Lease Right Of Use Assets Liabilities Amortization Net-
Increase Decrease In Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer-
Capitalized Contract Cost Amortization-
Increase Decrease In Contract With Customer Liability-
Increase Decrease In Accrual For Taxes Other Than Income Taxes-1.53
Operating Lease Right Of Use Amortization0.95
Finance Lease Right Of Use Asset Amortization0.01
Income taxes0.00
Unrealized Gain (Loss) on Derivatives0.00
Accounts Receivable-1.54
Increase (Decrease) in Accounts Payable and Accrued Liabilities58.75
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-25.18
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-10.47
Discontinued operations0.00
Net Cash flow from Operating Activities-103.53
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.19
Short-term Investments Proceeds0.00
Payments to Acquire Available-for-sale Securities, Debt-176.47
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-176.29
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.64
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-192.06
Capital Expenditures Incurred But Not Yet Paid-
Initial Pubic Offering Costs Incurred But Not Yet Paid-
Deferred Initial Public Offering Costs-
Vesting Of Early Exercised Stock Options-
Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plans-
Payments For Deferred Initial Public Offering Costs-
Proceeds From Issuance Of Common Stock Convertible Preferred Stock And Warrants-
Proceeds From Issuance Of Common Stock Stock Purchase Agreement-
Proceeds From Issuance Of Common Stock Series X Preferred Stock And Warrants-
Proceeds From Issuance Of Common Stock Preferred Stock And Warrants-
Proceeds From Issuance Of Common Stock In Underwritten Public Offering376.91
Finance Lease Principal Payments-0.05
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents196.18
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities383.62
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-103.34
Total Cash Flow103.81
4 historic quarters locked

Sign in to unlock the full Cidara Therapeutics Inc cash flow history.

Sign In Create Free Account

About Cidara Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001610618-25-000096

Figures are derived from filed reports and may be restated. Historical data is subject to revision.